In the high-stakes world of biopharmaceutical manufacturing, the phrase "tech transfer" is often treated as a logistical checkbox—a documented handoff of protocols from R&D to a pilot plant, or from a drug developer to a Contract Development and Manufacturing Organization (CDMO). However, beneath the surface of validated SOPs and regulatory filings lies a silent, costly crisis: the loss of "tacit knowledge."
Tacit knowledge is the expertise that resides in the minds of scientists, engineers, and operators—the "feel" for a process, the intuition built through failed experiments, and the subtle adjustments made at the bench that never make it into a formal report. As the biopharma industry undergoes a seismic shift toward outsourcing and grapples with an aging workforce, this intangible asset is evaporating, leading to significant delays, quality failures, and billions of dollars in lost value.
The Anatomy of the Problem: Why Documentation Isn’t Enough
Technology transfer is a recurring necessity throughout the lifecycle of a drug. It happens during the transition from CMC (Chemistry, Manufacturing, and Controls) development to clinical supply, during scale-up for commercialization, and even post-approval when network optimization requires site changes.
According to Ryan Chen, director of Product Marketing at ValGenesis, the industry’s reliance on document-centric systems has created a blind spot. "Technology transfer occurs repeatedly across the lifecycle," Chen explains. "But the problem is that our current regulatory and quality frameworks are designed to capture what is written, not what is known."
The industry’s heavy reliance on outsourcing exacerbates this. With over 86% of biopharma companies now outsourcing at least some portion of their manufacturing, the movement of processes between disparate organizations has become the norm. Yet, patents and published literature capture only the "what"—the final product of a successful process—rather than the "how"—the critical decision-making pathway that led to that success.
Chronology of a Knowledge Gap: From Academia to Industry
The most significant point of failure often occurs at the very beginning of the pipeline: the transfer of technology from academic labs to commercial settings.
The Research-to-GMP Divide
In an academic setting, processes are intentionally exploratory. They are designed for flexibility, speed, and innovation. A researcher might spend years mastering a specific cell culture technique, learning to interpret subtle visual cues in the bioreactor or identifying the exact point of harvest based on subjective observations.
When this work is licensed and moves to a commercial entity, it hits a wall of rigid standardization. Research data is often messy, and the "undocumented tacit knowledge" associated with these processes is rarely translated into the stringent, regulatory-compliant systems required for Good Manufacturing Practice (GMP).
The "Failure" Memory
Perhaps the most damaging loss occurs regarding failed experiments. In a scientific career, the knowledge gained from what didn’t work is as valuable as the success itself. This collective wisdom is usually passed down through informal mentoring and conversation within a lab group. When a lead scientist retires or a startup is acquired and its original team is displaced, that "tribal knowledge" is permanently erased. The industry loses the history of the process, forcing new teams to repeat the same mistakes, thereby inflating costs and delaying time-to-market.
Supporting Data: The High Cost of Silence
The financial implications of ignoring knowledge management are no longer theoretical. Merck, for instance, has publicly documented a $125 million gain in value attributable to structured knowledge management initiatives over a ten-year period. This figure highlights the massive opportunity cost for firms that fail to treat knowledge as a capital asset.
The industry is currently facing a "perfect storm" that makes this issue more urgent than ever:
- The Demographic Cliff: Approximately 11,000 baby boomers reach retirement age every day in the United States. This represents a massive exodus of veteran scientists and manufacturing leads who carry decades of experiential knowledge.
- The Layoff Surge: The biopharma sector saw a 16% rise in layoffs in 2025, with manufacturing and CDMO functions hit particularly hard. When institutional memory is purged through layoffs, the ability to troubleshoot complex biological processes vanishes with the workforce.
- Regulatory Underappreciation: While the PDA’s Technical Report No. 65 advocates for capturing tacit knowledge as a best practice, there is a glaring absence of a regulatory mandate. The ISPE Good Practice Guide on Knowledge Management admits that in a field obsessed with documentation, tacit knowledge is "arguably underappreciated."
Advanced Modalities: The Stakes Are Higher
If tacit knowledge loss was a nuisance for small-molecule drug manufacturing, it has become a catastrophic risk for cell and gene therapies (CGTs). Unlike the production of a chemical pill, where the process is relatively stable and terminal sterilization is possible, CGT manufacturing involves living systems that are highly sensitive to the environment and the operator.
The Human Factor in CAR-T
In the production of CAR-T cell therapies, the process is inherently manual. Steps such as cell isolation, expansion, and harvesting rely heavily on the dexterity and technique of the operator.
"Advanced modalities introduce greater biological variability, complex potency assays, and sensitivity to operator technique," says Chen. "In CAR-T manufacturing, the interpretation of quality control assays—like flow cytometry—can vary meaningfully between operators. An SOP alone cannot capture the nuance of a technician’s hand movements or their visual assessment of cell health."
Because these therapies cannot be terminally sterilized, any deviation caused by a lack of deep-seated "tacit" understanding can lead to batch failure. In a world where a single dose of a therapy can cost hundreds of thousands of dollars, the cost of a "lost process" due to poor knowledge transfer is not just an operational inefficiency—it is a significant threat to patient outcomes and business viability.
Official Responses and Strategic Recommendations
Industry leaders and quality experts are beginning to shift their approach, moving away from viewing tech transfer as a late-stage operational event and toward an integrated "Knowledge Lifecycle" model.
Designing for Transfer
To mitigate these risks, firms are being encouraged to "design for transfer" from the earliest phases of development. This involves:
- Early Institutionalization: Embedding knowledge management systems into the Quality Management System (QMS) during the R&D phase, rather than waiting for the clinical stage.
- Analytical Readiness: Investing heavily in objective, automated analytical tools that reduce the reliance on subjective operator interpretation.
- Governance and Discipline: Selecting CDMO partners based on their "modality expertise" rather than just cost or capacity, and ensuring that change-control discipline is enforced from day one.
- Mentorship and Documentation: Creating formal "knowledge hand-off" protocols where senior scientists are required to document the "why" and "what if" behind their decisions, not just the successful outcomes.
Implications for the Future of Biopharma
The transition of the pharmaceutical industry toward more complex, biological-based therapies means that the "black box" of manufacturing is becoming more opaque. If the industry continues to rely on legacy documentation practices while losing its most experienced human capital, the risk of systemic failure will only grow.
The path forward requires a cultural shift. Companies must stop viewing knowledge management as a burden of compliance and start viewing it as a competitive advantage. As Ryan Chen notes, the winners in the next decade of biopharma will be those who treat tacit knowledge as a core component of their tech transfer strategy.
For the patient waiting for life-saving gene therapy, the difference between a successful treatment and a failed batch may well depend on whether the knowledge lost in a laboratory three years ago was successfully captured, preserved, and transferred to the operator standing in the cleanroom today. The industry’s ability to turn "what we know" into "what we do" is no longer just an academic pursuit—it is the bedrock of modern medicine.
About the Author
